Estamos realizando la búsqueda. Por favor, espere...
1582
37
170
29108
4409
2600
347
389
Abstract: Nursing home residents (NHR) have been targeted as a vaccination priority due to their higher risk of worse outcome after COVID-19 infection. The mRNA-based vaccine BTN2b2 was first approved in Europe for NHRs. The assessment of the specific vaccine immune response (both humoral and cellular) at long term in NHRs has not been addressed yet. A representative sample of 624 NHR subjects in Northern region of Spain was studied to assess immune response against full vaccination with BTN2b2. The anti-S1 antibody levels and specific T cells were measured at two and six months after vaccination. 24.4% of NHR had a previous infection prior to vaccination. The remaining NHR were included in the full vaccination assessment group (FVA). After two months, a 94.9% of the FVA presented anti-S1 antibodies, whereas those seronegative without specific cellular response were 2.54%. At long-term, the frequency of NHR within the FVA group with anti-S1 antibodies at six months were 88.12% and the seronegative subjects without specific cellular response was 8.07%. The cellular immune assays complement the humoral test in the immune vaccine response assessment. Therefore, the cellular immune assessment in NHRs allows for the fine tuning of those seronegative subjects with potential competent immune responses against the vaccine.
Fuente: Vaccines 2021, 9(12), 1429
Editorial: MDPI
Fecha de publicación: 02/12/2021
Nº de páginas: 9
Tipo de publicación: Artículo de Revista
DOI: 10.3390/vaccines9121429
ISSN: 2076-393X
Url de la publicación: https://www.mdpi.com/2076-393X/9/12/1429
Consultar en UCrea Leer publicación
SAN SEGUNDO, DAVID
COMINS-BOO, ALEJANDRA
LAMADRID-PEROJO, PATRICIA
IRURE-VENTURA, JUAN
JOSE MARIA CASTILLO OTI
WALLMAN, REINHARD
CALVO-MONTES, JORGE
MÉNDEZ-LEGAZA, JOSÉ MANUEL
BAAMONDE-CALZADA, CARMELA
SÁNCHEZ-MOLINA, ISABEL
LECUE-MARTÍNEZ, MARINA
VENTISCA-PÉREZ, SILVIA
BATLLE-LÓPEZ, ANA
MARCOS LOPEZ HOYOS
Volver